Origin Endoscopy

Executive Summary

Origin Endoscopy is a privately held biotechnology company developing a novel hydrogel platform for ultrafast bio-adhesion and submucosal injection, primarily targeting gastrointestinal endoscopy applications. Founded in 2016 and headquartered in San Carlos, California, the company's technology aims to improve therapeutic outcomes by enabling precise, rapid delivery of agents to targeted submucosal tissue layers. Despite limited public information, the platform's versatility suggests potential for multiple indications in drug delivery and endoscopic procedures. The company is in early stages, with no disclosed funding or pipeline details, but its innovative approach addresses unmet needs in mucosal barrier protection and local drug delivery. As a private entity, progress may be inferred from partnerships or intellectual property filings. The company's success hinges on validating its platform clinically and securing strategic collaborations to advance toward the market.

Upcoming Catalysts (preview)

• Q3 2026Series A or Seed Funding Announcement70% success
• Q4 2026Preclinical Proof-of-Concept Data Release60% success
• 2027Strategic Partnership with Endoscopy Device Company50% success